Biopharmaceutical company Corvus Pharmaceuticals, Inc. (CRVS) announced Thursday updated data from its ongoing Phase 1 study investigating the potential for CPI-006 to provide a novel immunotherapy approach for patients with COVID-19.
from RTT - Biotech https://ift.tt/35q3NAe
via IFTTT
No comments:
Post a Comment